do young women get breast cancer and what are the similarities between breast cancer in young women with BRCA1 mutations and breast cancer among young women in the general population without a family history?
How should we screen for these highly proliferative tumors that may not be detectable by routine mammography? Why are they more aggressive than other breast tumors? Why are women of African ancestry more likely to develop ER negative, HER2 negative (basal-like/triple negative) breast cancers? Most importantly, how can we best achieve the promise of individualized therapies? Dr. Olopade’s approach has been family based and her group has amassed resources. Mid-year Progress Report: In the Nigeria project, as a unique practice model, Dr. Olopade has established the first collaborative team of investigators qualified to conduct breast cancer clinical trials in Nigeria, the most populous country in sub-Saharan African with a population of 140 million. Thanks to BCRF, they are on the path of transforming breast cancer care in Africa. The infrastructure is evolving and the investigators are using this study to learn how to conduct trials. They have had two audits and both sites are performing
- do young women get breast cancer and what are the similarities between breast cancer in young women with BRCA1 mutations and breast cancer among young women in the general population without a family history?
- What have the specific studies of the oral contraceptive pill and breast cancer shown in young black women?
- What are the similarities and differences between BRCA1 and BRCA2 mutations?